Welcome to our dedicated page for Procept Biorobotics SEC filings (Ticker: PRCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PROCEPT BioRobotics Corporation (PRCT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. PROCEPT BioRobotics is a surgical robotics company in urology, listed on The Nasdaq Global Market under the symbol PRCT, and its filings offer detailed information on business operations, financial performance, risk factors, and governance.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for discussions of revenue from AQUABEAM and HYDROS Robotic Systems, segment details such as U.S. and international revenue, gross margins, operating expenses, and liquidity. Current reports on Form 8-K include items such as quarterly financial results, changes to executive compensation arrangements, and other material events affecting the company.
Through this page, users can also track executive and director compensation arrangements and changes to severance or change-of-control agreements, as disclosed in 8-K exhibits. While insider transaction reports on Form 4 are not listed in the excerpts above, Stock Titan’s filings interface is designed to surface such ownership changes when available, alongside 10-K, 10-Q, and 8-K filings.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, helping readers quickly understand topics such as revenue trends, installed base growth, non-GAAP measures like Adjusted EBITDA, and risk factor highlights. Real-time updates from the SEC’s EDGAR system ensure that new PRCT filings appear promptly, allowing investors, analysts, and researchers to follow PROCEPT BioRobotics’ regulatory and financial reporting history in one place.
PROCEPT BioRobotics EVP, CLO and Corporate Secretary Alaleh Nouri sold 3,243 shares of common stock in open-market transactions. The sales on
PROCEPT BioRobotics Corp director-linked entity Kestrel Fund, L.P. reported open-market purchases of 426,262 shares of common stock over several days. The buys occurred on March 5, 6 and 9, 2026 at weighted average prices generally between the low $20s and mid $20s per share, as detailed in price ranges in the footnotes. The filing also shows 35,152 shares held directly and 14,363 shares held indirectly by The 2:22 DNA Trust as of March 5, 2026. Antal Rohit Desai, a director and managing partner of CPMG, Inc., may be deemed to share voting and investment power over Kestrel Fund holdings but disclaims beneficial ownership except to the extent of any pecuniary interest.
PROCEPT BioRobotics President and CEO Larry L. Wood received equity awards on March 5, 2026. He was granted 103,653 stock options at an exercise price of
The RSUs vest over four years, with one-quarter vesting on March 5, 2027 and the remainder vesting quarterly over 36 months, conditioned on continued service. The stock options vest monthly over four years from March 5, 2026, also subject to continued employment or service.
PROCEPT BioRobotics EVP, CLO and Corporate Secretary Nouri Alaleh reported mixed equity transactions. On March 6, 2026, Alaleh sold 6,892 shares of Common Stock at an average price of $23.7019, with the shares sold to cover tax withholding obligations tied to vesting of restricted and performance stock units. Following this sale, direct ownership of Common Stock was 114,264 shares.
On March 5, 2026, Alaleh received 43,811 shares of Common Stock as a grant, structured as restricted stock units that vest over four years, beginning with one-quarter on March 5, 2027, and the remainder in quarterly installments. Alaleh was also granted a stock option for 29,615 shares, vesting in equal monthly installments over four years starting March 5, 2026, contingent on continued service.
PROCEPT BioRobotics EVP & CFO Kevin Waters reported a mix of equity awards and a tax-related share sale. On March 5, he received 47,462 restricted stock units and a stock option for 32,576 shares, both at no cash cost, with multi‑year vesting starting in March 2026–2027.
On March 6, he sold 6,721 shares of common stock at an average price of $23.7019 per share to cover tax withholding obligations tied to vesting RSUs and performance stock units. After the sale, he directly held 152,264 shares of common stock.
PROCEPT BioRobotics Corp director Dan Puckett received new equity awards. On March 5, 2026, he was granted stock options for 8,897 shares at an exercise price of $0.00 per share and 5,476 shares of common stock in the form of restricted stock units.
One-third of the stock options and one-third of the RSUs are scheduled to vest on March 5, 2027, with the remaining two-thirds of each award vesting in equal annual installments over the following two years, subject to his continued service with the company.
PROCEPT BioRobotics Corp director Dan Puckett filed an initial ownership report on Form 3. The filing lists him as a director of the company and does not report any share purchases, sales, acquisitions, or dispositions at this time.